文献速递肝病消化道肿瘤与早癌

低水平乙肝病毒血症较检测不到病毒血症增加未治疗代偿期肝硬化患者肝细胞癌风险

Low Level of Hepatitis B Viremia Compared With Undetectable Viremia Increases the Risk of Hepatocellular Carcinoma in Patients With Untreated Compensated Cirrhosis.
PubMed 文献 · Am J Gastroenterol · 2023-01-09

该回顾性研究分析627例未治疗的慢性乙型肝炎代偿期肝硬化患者,比较低水平病毒血症(HBV DNA 15-2,000 IU/mL)与检测不到HBV DNA患者的肝细胞癌及肝脏相关临床事件风险。多变量分析显示低水平病毒血症组肝细胞癌风险显著更高(校正HR 2.36,P=0.002),倾向评分匹配队列中亦更高(HR 2.16,P=0.014)。作者建议此类患者应接受抗病毒治疗。

要点

  • 未治疗代偿期肝硬化患者中,低水平病毒血症组肝细胞癌风险显著高于检测不到病毒血症组(校正HR 2.36,P=0.002)。
  • 倾向评分匹配队列中低水平病毒血症组肝细胞癌风险为检测不到组的2.16倍(P=0.014)。
  • 肝脏相关临床事件在低水平病毒血症组有升高趋势但未达统计学显著(匹配队列HR 1.14,P=0.50)。

核心结论

  • 与检测不到HBV DNA的患者相比,代偿期肝硬化伴低水平病毒血症患者肝细胞癌风险显著更高,作者建议这些患者应接受抗病毒治疗。

研究设计与样本

  • 回顾性分析627例未治疗的慢性乙型肝炎代偿期肝硬化患者,比较低水平病毒血症(HBV DNA 15-2,000 IU/mL)与检测不到HBV DNA患者的肝细胞癌及肝脏相关临床事件风险,抗病毒治疗启动时删失。

主要发现

  • 患者平均年龄54.7岁,64.4%为男性。
  • 研究期间59例发生肝细胞癌(检测不到组20例,低水平病毒血症组39例),年发病率2.44/100人年。
  • 多变量分析显示低水平病毒血症组肝细胞癌风险显著高于检测不到组(校正HR 2.36,P=0.002)。
  • 在204例倾向评分匹配队列中,低水平病毒血症组肝细胞癌风险为检测不到组的2.16倍(P=0.014)。
  • 肝脏相关临床事件发生于121例患者,年发病率5.25/100人年;倾向评分匹配队列中低水平病毒血症组肝脏相关事件风险有升高趋势但未达统计学显著(HR 1.14,P=0.50)。

临床怎么用

  • 作者建议代偿期肝硬化伴低水平病毒血症(HBV DNA 15-2,000 IU/mL)患者应接受抗病毒治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The initiation of antiviral treatment in patients with chronic hepatitis B with compensated cirrhosis and low-level viremia (LLV; HBV DNA 15-2,000 IU/mL) remains controversial. We sought to compare the long-term outcomes of these untreated patients according to their viremic status. METHODS: Six hundred twenty-seven untreated patients with chronic hepatitis B with compensated cirrhosis were analyzed retrospectively. The risk of hepatocellular carcinoma (HCC) and liver-related clinical events, including hepatic decompensation, were compared between patients with LLV and undetectable HBV DNA. Patients who received antiviral treatment were censored during treatment initiation. RESULTS: The mean age of the patients was 54.7 years, 64.4% of whom were male. During the study period, 59 patients developed HCC (20 and 39 in the undetectable and LLV groups, respectively) with an annual incidence of 2.44/100 person-years. Multivariable analysis revealed that the LLV group was associated with a significantly higher risk of HCC (adjusted hazard ratio: 2.36, P = 0.002) than the undetectable group. In the 204 propensity score-matched cohort, the LLV group had a 2.16-fold greater risk of HCC than the undetectable group ( P = 0.014). Liver-related clinical events occurred in 121 patients with an annual incidence of 5.25/100 person-years. Despite not reaching statistical significance, the LLV group tended to have a higher risk of liver-related events in the propensity score-matched cohort (hazard ratio: 1.14, P = 0.50). DISCUSSION: Compared with patients with undetectable HBV DNA, those with compensated cirrhosis and LLV had a significantly higher risk of HCC. Antiviral treatment should be advised for these patients.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Yang J, Choi WM, Shim JH, et al. Low Level of Hepatitis B Viremia Compared With Undetectable Viremia Increases the Risk of Hepatocellular Carcinoma in Patients With Untreated Compensated Cirrhosis. Am J Gastroenterol. 2023. PMID: 36622283. doi:10.14309/ajg.0000000000002181

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。